AI-Discovered Drug Shows Potential to Slow Aging in Clinical Study, Biotech Says
Six proteomic aging clocks and 42 trial participants showed rentosertib reversed predicted biological age while lung function improved dose-dependently, Insilico said.
- Insilico Medicine announced in Nature Biotechnology that rentosertib, an AI-discovered drug candidate, reversed predicted biological age in patients with idiopathic pulmonary fibrosis.
- Using its generative AI platform, Insilico identified TNIK as a target relevant to both aging and fibrosis, designing rentosertib to suppress senescence drivers and modulate accelerated aging pathways.
- Analyzing 12-week proteomic data from 42 patients, researchers applied six independently developed aging clocks; all six unanimously indicated rentosertib reduced predicted biological age versus placebo.
- On Tuesday, September 8, 2026, CEO Alex Zhavoronkov will present findings at the Nature conference in Paris, establishing a proof-of-concept framework for integrating aging biomarkers into standard clinical trials.
- Insilico reported total revenue of approximately $106 million in the first half of 2026, achieving its first profitable half-year since listing, with major collaboration contracts exceeding $11 billion.
58 Articles
58 Articles
New York Post
Drug developed for lung disease may slow biological aging in surprising ‘bonus’
In a new study, the experimental lung disease drug rentosertib made patients appear biologically younger by an average of three to four years.
AI-Designed Drug Might Slow Biological Aging
A drug dreamed up by artificial intelligence just delivered a small but buzzy result: it appeared to make people "younger" on paper. In a Nature Biotechnology study, Insilico Medicine reports that its experimental pill, rentosertib , nudged down biological age markers in a 12-week trial of 42 people, while those on...
AI-Designed Drug for Lung Disease Shows Signs of Turning Back Biological Clocks
An AI-designed drug for incurable lung fibrosis reduced predicted biological age by 3-4 years across six independent proteomic clocks in a small Phase 2a trial. While caveats remain, the consistency of results offers a new template for testing geroprotective effects in disease studies.
Coverage Details
Bias Distribution
- 36% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
